A proof-of-concept trial investigating metformin as an add-on treatment for mild or moderate SLE demonstrated that metformin down-regulated the NETs mtDNA-PDC-IFNα pathway, leading to clinical improvement of SLE and reduced its reliance on prednisolone (133). This evidence concerns the gene PDC and systemic lupus erythematosus.